Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ramulus Cinnamomi, known as Guizhi in Traditional Chinese Medicine (TCM), consists of the dried twigs of *Cinnamomum cassia* (L.) Presl. It is a complex botanical preparation that has been documented in the Chinese Pharmacopoeia since 1973. The extract contains over 120 chemical compounds, including volatile oils such as cinnamaldehyde and organic acids like cinnamic acid. As a multi-component botanical mixture, it modulates several biological pathways, including the PI3K/Akt, Akt/ERK, and PLK1/CDK1/Cyclin B signaling axes. Research has demonstrated its potential therapeutic activities, including anti-inflammatory, antibacterial, antiviral, antipyretic, and antitumor effects. It is primarily investigated for conditions such as colon cancer, cardiovascular disease, arthritis, and gastrointestinal dysfunction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ramulus cinnamomi.